24 04, 2026

New publication in Biomaterials

2026-04-24T11:54:56+02:00April 24th, 2026|EV characterization, exosomes, extracellular vesicle, Macrophages, microRNA, microRNA services, microRNAs, RegenerativeMedicine, WoundHealing|0 Comments

Huge congrats to Cansu Gorgun and the teams at Royal College of Surgeons in Ireland (RCSI) and Trinity College Dublin on their new publication in Biomaterials! This study is a fascinating look at how we can "train" macrophages to do two things at once. By reprogramming their metabolism, the team produced hybrid M1/M2 extracellular vesicles — a "dual-action" package that combines pro-inflammatory and pro-healing signals. We were lucky enough to support this work at 𝗧𝗔𝗺𝗶𝗥𝗡𝗔 by characterizing the EV miRNA cargo and looking into the functional implications of these hybrid vesicles. It’s a clever, elegant approach that opens new possibilities for smarter wound healing, tissue repair, and cell-free regenerative therapies. Fantastic work by everyone involved! TAmiRNA EV [...]

11 03, 2026

TAmiRNA @ RNA Leaders Europe Conference

2026-03-11T10:10:00+01:00March 11th, 2026|biomarker, circulating miRNAs, Conference, microRNA, microRNA services, NGS, RNA|Comments Off on TAmiRNA @ RNA Leaders Europe Conference

Vienna, Austria – 17.-19. March 2026 TAmiRNA is pleased to announce that CEO/CSO Matthias Hackl and Head of R&D Teresa Krammer will attend the upcoming RNA Leaders Europe Conference, one of the leading industry events dedicated to RNA therapeutics, innovation, and translational research. RNA Leaders Europe brings together key stakeholders from academia, biotech, pharma, and technology providers to discuss the latest scientific advances, regulatory developments, and commercialization strategies in the rapidly evolving RNA field. As a specialized provider of RNA-focused services, TAmiRNA supports partners worldwide with comprehensive solutions ranging from RNA profiling and biomarker discovery to advanced bioinformatics and customized data analysis. The conference offers an excellent platform to exchange insights, explore collaborations, and discuss how cutting-edge [...]

2 03, 2026

Independent Validation of Circulating microRNAs as Biomarkers in Type 1 Diabetes

2026-03-02T10:12:31+01:00March 2nd, 2026|biomarker, circulating miRNAs, Illumina NewSeq2000, microRNA, microRNA services, NGS, T1D, Type 1 Diabetes|Comments Off on Independent Validation of Circulating microRNAs as Biomarkers in Type 1 Diabetes

TAmiRNA is proud to contribute to a newly published peer-reviewed study demonstrating the independent validation of circulating microRNAs (miRNAs) as biomarkers in adolescents with long-standing type 1 diabetes (T1D). The study, published in PLOS ONE (2026), strengthens growing evidence that circulating microRNAs serve as minimally invasive biomarkers with potential applications in disease monitoring and precision medicine. Study Overview: microRNA Biomarkers in Adolescent Type 1 Diabetes Reliable biomarkers are essential for improving disease monitoring and long-term management of type 1 diabetes. MicroRNAs — small, non-coding RNA molecules regulating gene expression — are detectable in blood and have emerged as promising non-invasive diagnostic and prognostic tools. This case-control study investigated previously reported circulating miRNAs in: 24 adolescents with type [...]

7 01, 2026

TAmiRNA Research on microRNA Biomarkers for Periprosthetic Joint Infections Featured on Wien Heute, One of Austria’s Most-Watched Regional News Programs

2026-01-21T08:39:17+01:00January 7th, 2026|biomarker, Illumina NewSeq2000, microRNA, microRNA services, miND, miND spike ins, miND spike-in, NGS, Osteoarthritis, quality, Synovial fluid|Comments Off on TAmiRNA Research on microRNA Biomarkers for Periprosthetic Joint Infections Featured on Wien Heute, One of Austria’s Most-Watched Regional News Programs

Research conducted by TAmiRNA in collaboration with the Michael Ogon Laboratory (Orthopädisches Spital Speising) on microRNA-based biomarkers for the early detection of periprosthetic joint infections (PJI) was recently featured on Wien Heute, one of Austria’s most widely viewed regional television news programs (ORF, January 3, 2026). The coverage highlights both the clinical relevance of the problem and the translational potential of novel molecular diagnostic approaches. Periprosthetic joint infections are among the most serious complications following hip and knee arthroplasty. Although the incidence is estimated at approximately 1-10%, PJIs are associated with substantial morbidity, prolonged treatment, and high healthcare costs. A major challenge in clinical practice remains the timely and reliable differentiation between infected and non-infected implants, particularly [...]

4 12, 2025

Synovial Fluid and Serum microRNA Signatures in Equine Osteoarthritis

2025-12-04T11:05:09+01:00December 4th, 2025|biomarker, Illumina NewSeq2000, microRNA, microRNA services, miND, miND spike ins, miND spike-in, NGS, Osteoarthritis, quality, Synovial fluid|Comments Off on Synovial Fluid and Serum microRNA Signatures in Equine Osteoarthritis

New research highlights the potential of circulating miRNAs as biomarkers for joint degeneration A new peer-reviewed study has been published in the International Journal of Molecular Sciences (IJMS): “Synovial Fluid and Serum MicroRNA Signatures in Equine Osteoarthritis.” This work provides important insights into how microRNAs (miRNAs) in serum and synovial fluid reflect the presence of osteoarthritis (OA) in horses. 🎯 Study Aim The researchers sought to identify disease-associated miRNAs that differ between healthy horses and horses with osteoarthritis. Their goal was to uncover molecular signatures that could support the development of novel biomarkers for early detection and monitoring of OA. 🔬 Methods Serum and synovial fluid samples were collected from healthy controls (n = 4) and horses [...]

26 11, 2025

TAmiRNA and Orthopaedic Hospital Speising Publish Landmark Data on promiR® for Accurate Diagnosis of Periprosthetic Joint Infections

2025-12-04T11:05:55+01:00November 26th, 2025|biomarkers in orthopaedics, Illumina NewSeq2000, microRNA, microRNA services, miND, miND spike ins, miND spike-in, NGS, periprosthetic joint infections, promiR, quality, Synovial fluid|Comments Off on TAmiRNA and Orthopaedic Hospital Speising Publish Landmark Data on promiR® for Accurate Diagnosis of Periprosthetic Joint Infections

On November 19th, 2025, the study “Synovial Fluid MicroRNA Biomarkers Enable Accurate Diagnosis of Hip and Knee Periprosthetic Joint Infections” by Frank et al. was published in the Journal of Bone and Joint Surgery. This peer-reviewed publication marks an important milestone in TAmiRNA’s biomarker development program and presents promiR®, our novel microRNA-based diagnostic panel designed to improve the pre-operative assessment of periprosthetic joint infections (PJIs). Clinical Challenge PJIs remain one of the most serious and difficult complications following total joint replacement. Current diagnostic methods—including inflammatory markers, imaging, and cultures—often lack sensitivity and specificity, especially for low-grade or culture-negative infections. Even advanced approaches such as PCR or next-generation sequencing can suffer from contamination risks and ambiguous [...]

11 11, 2025

Distinct microRNA profiles in human amniotic membrane its vesicular and non-vesicular secretome revealed

2025-11-11T08:44:13+01:00November 11th, 2025|exosomes, extracellular vesicle, Illumina NewSeq2000, microRNA, microRNA services, miND, miND spike ins, miND spike-in, NGS, quality|Comments Off on Distinct microRNA profiles in human amniotic membrane its vesicular and non-vesicular secretome revealed

Vienna, Austria – November 2025 TAmiRNA scientist have contributed significantly to a new study published by the Ludwig Boltzmann Institute for Traumatology, which is titled “Distinct miRNA profiles in human amniotic tissue and its vesicular and non-vesicular secretome”. The article was published in Frontiers in Cell and Developmental Biology on October 29th 2025. Human amniotic membrane (hAM) has been used in tissue regeneration and wound healing applications. In this study, the miND® small RNA-sequencing workflow was applied to generate fresh insights into the microRNA composition of two spatially and physiologically distinct regions of the human amniotic membrane (hAM) and its secreted extracellular vesicles (EVs) and protein-bound miRNAs. The work highlights how advanced analytical workflows can uncover tissue- [...]

14 10, 2025

hepatoMX Project Kickoff: TAmiRNA and You2Yourself Join Forces to Develop a Groundbreaking Urinary microRNA Diagnostic for Liver Disease

2025-10-14T08:25:31+02:00October 14th, 2025|biomarker, Biomarker Discovery, biomarkers, hepatoMX, Illumina NewSeq2000, microRNA services, microRNAs, miND, miND spike ins, NGS, sequencing, small RNA-sequencing, smallRNA|Comments Off on hepatoMX Project Kickoff: TAmiRNA and You2Yourself Join Forces to Develop a Groundbreaking Urinary microRNA Diagnostic for Liver Disease

We are excited to announce the official start of the EUREKA Eurostars project hepatoMX — a three-year collaboration between You2Yourself (Y2Y), a Dutch company specializing in small RNA-based early disease detection, and TAmiRNA GmbH, an Austrian SME with expertise in microRNA biomarker discovery and diagnostic test development (hepatomiR®). The project officially started on April 1, 2025, and aims to revolutionize the early detection of metabolic liver disease. The hepatoMX project will leverage TAmiRNA’s clinical expertise in liver diagnostics and Y2Y’s unique Urimon cohort that captures the dynamics of disease development to deliver a validated diagnostic test utilizing a proprietary urinary microRNA biomarker panel to identify early-stage liver disease in a simple and non-invasive manner. This innovative approach [...]

9 10, 2025

Microvascular microRNA Signatures in Sepsis: A High-Resolution View

2025-10-09T10:29:18+02:00October 9th, 2025|biomarker, Biomarker Discovery, biomarkers, Illumina NewSeq2000, laser microdissection (LMD), microRNA services, microRNAs, miND, miND spike ins, NGS, sequencing, small RNA-sequencing, smallRNA|Comments Off on Microvascular microRNA Signatures in Sepsis: A High-Resolution View

Sepsis drives profound microvascular injury, particularly in the kidney. But how do microRNAs (miRNAs) - the small regulators of gene expression - respond within distinct vascular compartments during this insult? A new study by Luxen et al.  published in Scientific Reports on October 2nd 2025 takes on this question using a clever methodological combination: laser microdissection (LMD) of microvascular subregions (arterioles, glomeruli, capillaries, postcapillary venules) followed by small RNA sequencing using TAmiRNA´s miND® workflow for highly sensitive and quantitative microRNA analysis. Why this approach matters Traditional microRNA profiling of whole tissues obscures spatial heterogeneity. With LMD, the authors could precisely isolate defined microvascular zones from kidney sections. Even with the tiny RNA yields from these isolated compartments, [...]

5 02, 2025

7Bioscience and TAmiRNA collaborate to expand access to our cutting-edge transcriptomics services

2025-02-04T11:11:02+01:00February 5th, 2025|biomarker, biomarkers, microRNA services, microRNAs, sequencing, smallRNA|Comments Off on 7Bioscience and TAmiRNA collaborate to expand access to our cutting-edge transcriptomics services

We are delighted to welcome 7Bioscience as the new distribution partner of TAmiRNA GmbH! With a strong track record in clinical and research molecular biology, 7Bioscience will support to offer TAmiRNA’s innovative service solutions to a broader audience. This partnership will enhance accessibility to our cutting-edge transcriptomics analysis. We look forward to a successful collaboration with 7Bioscience and the opportunities this partnership will bring!

Go to Top